Suvorexant (BioDeep_00000760356)

   


代谢物信息卡片


Suvorexant(MK-4305)

化学式: C23H23ClN6O2 (450.1570928)
中文名称: 苏沃雷生
谱图信息: 最多检出来源 () 0%

分子结构信息

SMILES: CC1CCN(CCN1C(=O)C2=C(C=CC(=C2)C)N3N=CC=N3)C4=NC5=C(O4)C=CC(=C5)Cl
InChI: InChI=1S/C23H23ClN6O2/c1-15-3-5-20(30-25-8-9-26-30)18(13-15)22(31)29-12-11-28(10-7-16(29)2)23-27-19-14-17(24)4-6-21(19)32-23/h3-6,8-9,13-14,16H,7,10-12H2,1-2H3/t16-/m1/s1

描述信息

D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants > D006993 - Hypnotics and Sedatives
C78272 - Agent Affecting Nervous System > C142786 - Orexin Receptor Antagonist
D018377 - Neurotransmitter Agents > D000068796 - Orexin Receptor Antagonists
N - Nervous system > N05 - Psycholeptics > N05C - Hypnotics and sedatives

同义名列表

2 个代谢物同义名

Suvorexant(MK-4305); Suvorexant



数据库引用编号

6 个数据库交叉引用编号

分类词条

相关代谢途径

Reactome(0)

BioCyc(0)

PlantCyc(0)

代谢反应

0 个相关的代谢反应过程信息。

Reactome(0)

BioCyc(0)

WikiPathways(0)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(0)

PharmGKB(0)

0 个相关的物种来源信息

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：

  • PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
  • NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
  • Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
  • Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。



文献列表

  • Hubert Bland, Xiaodong Li, Eric Mangin, Ka Lai Yee, Christopher Lines, W Joseph Herring, Gillian Gillespie. Effects of Bedtime Dosing With Suvorexant and Zolpidem on Balance and Psychomotor Performance in Healthy Elderly Participants During the Night and in the Morning. Journal of clinical psychopharmacology. 2021 Jul; 41(4):414-420. doi: 10.1097/jcp.0000000000001439. [PMID: 34181362]
  • Santosh Kumar Prajapati, Sairam Krishnamurthy. Non-selective orexin-receptor antagonist attenuates stress-re-stress-induced core PTSD-like symptoms in rats: Behavioural and neurochemical analyses. Behavioural brain research. 2021 02; 399(?):113015. doi: 10.1016/j.bbr.2020.113015. [PMID: 33212086]
  • Yelizaveta Sher, Beatrice Rabkin, José R Maldonado, Paul Mohabir. COVID-19-Associated Hyperactive Intensive Care Unit Delirium With Proposed Pathophysiology and Treatment: A Case Report. Psychosomatics. 2020 Sep; 61(5):544-550. doi: 10.1016/j.psym.2020.05.007. [PMID: 32591212]
  • Britni Skillman, Sarah Kerrigan. CYP450-Mediated metabolism of suvorexant and investigation of metabolites in forensic case specimens. Forensic science international. 2020 Jul; 312(?):110307. doi: 10.1016/j.forsciint.2020.110307. [PMID: 32473525]
  • M Yamanaka, H Iwata, K Masuda, M Araki, Y Okuno, M Okamura, J Koiwa, T Tanaka. A novel orexin antagonist from a natural plant was discovered using zebrafish behavioural analysis. European review for medical and pharmacological sciences. 2020 05; 24(9):5127-5139. doi: 10.26355/eurrev_202005_21207. [PMID: 32432777]
  • Britni Skillman, Sarah Kerrigan. Identification of Suvorexant in Blood Using LC-MS-MS: Important Considerations for Matrix Effects and Quantitative Interferences in Targeted Assays. Journal of analytical toxicology. 2020 Apr; 44(3):245-255. doi: 10.1093/jat/bkz083. [PMID: 31788700]
  • Rebecca E Wrishko, Jacqueline B McCrea, Ka Lai Yee, Wen Liu, Deborah Panebianco, Eric Mangin, Manu Chakravarthy, Maria P Martinez-Cantarin, Walter K Kraft. Effect of CYP3A Inhibition and Induction on the Pharmacokinetics of Suvorexant: Two Phase I, Open-Label, Fixed-Sequence Trials in Healthy Subjects. Clinical drug investigation. 2019 May; 39(5):441-451. doi: 10.1007/s40261-019-00764-x. [PMID: 30810914]
  • Muzaffar Iqbal, Nasr Y Khalil, Essam Ezzeldin, Khalid A Al-Rashood. Simultaneous Detection and Quantification of Three Novel Prescription Drugs of Abuse (Suvorexant, Lorcaserin and Brivaracetam) in Human Plasma by UPLC-MS-MS. Journal of analytical toxicology. 2019 Apr; 43(3):203-211. doi: 10.1093/jat/bky078. [PMID: 30295849]
  • Muzaffar Iqbal, Essam Ezzeldin, Nasr Y Khalil, Prawez Alam, Khalid A Al-Rashood. UPLC-MS/MS determination of suvorexant in urine by a simplified dispersive liquid-liquid micro-extraction followed by ultrasound assisted back extraction from solidified floating organic droplets. Journal of pharmaceutical and biomedical analysis. 2019 Feb; 164(?):1-8. doi: 10.1016/j.jpba.2018.10.005. [PMID: 30339947]
  • Masaru Nakamura, Takahiko Nagamine. Suvorexant as an orexin antagonist may regulate serum glucose levels in psychiatric patients with insomnia. Psychiatry and clinical neurosciences. 2017 Dec; 71(12):844. doi: 10.1111/pcn.12608. [PMID: 28945327]
  • Sydney Sullinger, Kelsie Bryand, Sarah Kerrigan. Identification of Suvorexant in Urine Using Liquid Chromatography-Quadrupole/Time-of-Flight Mass Spectrometry (LC-Q/TOF-MS). Journal of analytical toxicology. 2017 Apr; 41(3):224-229. doi: 10.1093/jat/bkw132. [PMID: 28035034]
  • Muzaffar Iqbal, Essam Ezzeldin, Nasr Y Khalil, Sara T A Al-Rashood, Khalid A Al-Rashood. Simple and Highly Sensitive UPLC-ESI-MS/MS Assay for Rapid Determination of Suvorexant in Plasma. Journal of analytical toxicology. 2017 Mar; 41(2):114-120. doi: 10.1093/jat/bkw111. [PMID: 28376227]
  • Paul J Coleman, Anthony L Gotter, W Joseph Herring, Christopher J Winrow, John J Renger. The Discovery of Suvorexant, the First Orexin Receptor Drug for Insomnia. Annual review of pharmacology and toxicology. 2017 01; 57(?):509-533. doi: 10.1146/annurev-pharmtox-010716-104837. [PMID: 27860547]
  • Mariah Carson, Sarah Kerrigan. Quantification of suvorexant in urine using gas chromatography/mass spectrometry. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences. 2017 Jan; 1040(?):289-294. doi: 10.1016/j.jchromb.2016.10.042. [PMID: 27825624]
  • Hiroshi Tsuneki, Kanta Kon, Hisakatsu Ito, Mitsuaki Yamazaki, Satoyuki Takahara, Naoki Toyooka, Yoko Ishii, Masakiyo Sasahara, Tsutomu Wada, Masashi Yanagisawa, Takeshi Sakurai, Toshiyasu Sasaoka. Timed Inhibition of Orexin System by Suvorexant Improved Sleep and Glucose Metabolism in Type 2 Diabetic db/db Mice. Endocrinology. 2016 Nov; 157(11):4146-4157. doi: 10.1210/en.2016-1404. [PMID: 27631554]
  • Donghui Cui, Tamara Cabalu, Ka Lai Yee, James Small, Xiaodong Li, Bo Liu, Cheri Maciolek, Sheri Smith, Wen Liu, Jacqueline B McCrea, Thomayant Prueksaritanont. In vitro and in vivo characterisation of the metabolism and disposition of suvorexant in humans. Xenobiotica; the fate of foreign compounds in biological systems. 2016 Oct; 46(10):882-95. doi: 10.3109/00498254.2015.1129565. [PMID: 26864332]
  • Atsuko Shihyakugari, Satoko Hori, Akiko Miki, Yasufumi Sawada. Induced next-day somnolence in an elderly patient taking suvorexant concomitantly with diltiazem. International journal of clinical pharmacology and therapeutics. 2016 Aug; 54(8):645-8. doi: 10.5414/cp202624. [PMID: 27191770]
  • S A Breidinger, R C Simpson, E Mangin, E J Woolf. Determination of suvorexant in human plasma using 96-well liquid-liquid extraction and HPLC with tandem mass spectrometric detection. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences. 2015 Oct; 1002(?):254-9. doi: 10.1016/j.jchromb.2015.07.056. [PMID: 26343269]
  • Jie Yin, Juan Carlos Mobarec, Peter Kolb, Daniel M Rosenbaum. Crystal structure of the human OX2 orexin receptor bound to the insomnia drug suvorexant. Nature. 2015 Mar; 519(7542):247-50. doi: 10.1038/nature14035. [PMID: 25533960]
  • Anthony L Gotter, Christopher J Winrow, Joseph Brunner, Susan L Garson, Steven V Fox, Jacquelyn Binns, Charles M Harrell, Donghui Cui, Ka Lai Yee, Mark Stiteler, Joanne Stevens, Alan Savitz, Pamela L Tannenbaum, Spencer J Tye, Terrence McDonald, Leon Yao, Scott D Kuduk, Jason Uslaner, Paul J Coleman, John J Renger. The duration of sleep promoting efficacy by dual orexin receptor antagonists is dependent upon receptor occupancy threshold. BMC neuroscience. 2013 Aug; 14(?):90. doi: 10.1186/1471-2202-14-90. [PMID: 23981345]
  • Hong Sun, William P Kennedy, Darren Wilbraham, Nicole Lewis, Nicole Calder, Xiaodong Li, Junshui Ma, Ka Lai Yee, Susan Ermlich, Eric Mangin, Christopher Lines, Laura Rosen, Jeffrey Chodakewitz, Gail M Murphy. Effects of suvorexant, an orexin receptor antagonist, on sleep parameters as measured by polysomnography in healthy men. Sleep. 2013 Feb; 36(2):259-67. doi: 10.5665/sleep.2386. [PMID: 23372274]
  • Gabrielle E Callander, Morenike Olorunda, Dominique Monna, Edi Schuepbach, Daniel Langenegger, Claudia Betschart, Samuel Hintermann, Dirk Behnke, Simona Cotesta, Markus Fendt, Grit Laue, Silvio Ofner, Emmanuelle Briard, Christine E Gee, Laura H Jacobson, Daniel Hoyer. Kinetic properties of "dual" orexin receptor antagonists at OX1R and OX2R orexin receptors. Frontiers in neuroscience. 2013; 7(?):230. doi: 10.3389/fnins.2013.00230. [PMID: 24376396]
  • Christopher J Winrow, Anthony L Gotter, Christopher D Cox, Scott M Doran, Pamela L Tannenbaum, Michael J Breslin, Susan L Garson, Steven V Fox, Charles M Harrell, Joanne Stevens, Duane R Reiss, Donghui Cui, Paul J Coleman, John J Renger. Promotion of sleep by suvorexant-a novel dual orexin receptor antagonist. Journal of neurogenetics. 2011 Mar; 25(1-2):52-61. doi: 10.3109/01677063.2011.566953. [PMID: 21473737]